High-Grade Glioma - Pipeline Review, H1 2018

June 2018 | 384 pages | ID: H20359F8038EN
Global Markets Direct

Abstracts

High-Grade Glioma - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2018, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 13, 1 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
• The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
High-Grade Glioma - Overview
High-Grade Glioma - Therapeutics Development
High-Grade Glioma - Therapeutics Assessment
High-Grade Glioma - Companies Involved in Therapeutics Development
High-Grade Glioma - Drug Profiles
High-Grade Glioma - Dormant Projects
High-Grade Glioma - Discontinued Products
High-Grade Glioma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for High-Grade Glioma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
High-Grade Glioma - Pipeline by AbbVie Inc, H1 2018
High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1 2018
High-Grade Glioma - Pipeline by AngioChem Inc, H1 2018
High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2018
High-Grade Glioma - Pipeline by Athenex Inc, H1 2018
High-Grade Glioma - Pipeline by Bayer AG, H1 2018
High-Grade Glioma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
High-Grade Glioma - Pipeline by Bristol-Myers Squibb Co, H1 2018
High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
High-Grade Glioma - Pipeline by Celgene Corp, H1 2018
High-Grade Glioma - Pipeline by Cellectar Biosciences Inc, H1 2018
High-Grade Glioma - Pipeline by Concordia International Corp, H1 2018
High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1 2018
High-Grade Glioma - Pipeline by Eisai Co Ltd, H1 2018
High-Grade Glioma - Pipeline by Ipsen SA, H1 2018
High-Grade Glioma - Pipeline by Karyopharm Therapeutics Inc, H1 2018
High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
High-Grade Glioma - Pipeline by Nektar Therapeutics, H1 2018
High-Grade Glioma - Pipeline by Northwest Biotherapeutics Inc, H1 2018
High-Grade Glioma - Pipeline by Novartis AG, H1 2018
High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
High-Grade Glioma - Pipeline by Sanofi, H1 2018
High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1 2018
High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
High-Grade Glioma - Pipeline by Targepeutics Inc, H1 2018
High-Grade Glioma - Pipeline by TheraBiologics Inc, H1 2018
High-Grade Glioma - Pipeline by Tocagen Inc, H1 2018
High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2018
High-Grade Glioma - Dormant Projects, H1 2018
High-Grade Glioma - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for High-Grade Glioma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

COMPANIES MENTIONED

AbbVie Inc
Advenchen Laboratories LLC
AngioChem Inc
Arog Pharmaceuticals Inc
Athenex Inc
Bayer AG
Bio-Cancer Treatment International Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
CBT Pharmaceuticals Inc
Celgene Corp
Cellectar Biosciences Inc
Concordia International Corp
DelMar Pharmaceuticals Inc
Eisai Co Ltd
Ipsen SA
Karyopharm Therapeutics Inc
Millennium Pharmaceuticals Inc
Nektar Therapeutics
Northwest Biotherapeutics Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Sanofi
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Targepeutics Inc
TheraBiologics Inc
Tocagen Inc
ZIOPHARM Oncology Inc